Search

Search Results

• 

  Intraparenchymal cerebral hemorrhage in a patient undergoing treatment with galcanezumab: the importance of adequate blood pressure control

  Yan Tereshko, Antonio Taglialatela, Iacopo Cancelli, Enrico Belgrado, Lorenzo Verriello, Giovanni Merlino, Mariarosaria Valente

  05-09-2025

  https://doi.org/10.4081/cc.2025.15786

  709

  PDF: 208
• 

  Exploring the cortical effect of monoclonal antibodies against CGRP ligand: a pilot study of the cortical silent period in migraine

  Gabriele Sebastianelli, Giulia Rosaria Melis, Chiara Abagnale, Francesco Casillo, Cherubino Di Lorenzo, Mariano Serrao, Gianluca Coppola

  09-05-2025

  https://doi.org/10.4081/cc.2025.15778

  1690

  PDF: 403
• 

  Prospective evaluation of aura during anti-calcitonin gene-related peptide monoclonal antibody therapy after 52 weeks of treatment

  Marina Romozzi, Andrea Burgalassi, Catello Vollono, Maria Albanese, Giulia Vigani, Francesco De Cesaris, Alberto Chiarugi, Paolo Calabresi, Luigi Francesco Iannone

  07-05-2024

  https://doi.org/10.4081/cc.2024.15762

  3915

  PDF: 623

• PO-43 | Eptinezumab in migraine patients unresponsive to prior subcutaneous CGRP(-R) monoclonal antibody treatment: a retrospective case series Elena Cresta, Irene Mattioli, Michele Di Pasquale, Alice Lanfranchi, Renata Rao, Alessandro Padovani | Neurology Unit and Headache Centre, Dipartimento di continuità di cura e fragilità, ASST Spedali Civili e Università degli studi di Brescia, Brescia, Italy

  Società Italiana per lo Studio delle Cefalee (SISC)

  06-11-2025

  https://doi.org/10.4081/cc.2025.15865

  303
• 

  Perceived ease-of-usability and local tolerability using CGRP monoclonal antibody autoinjectors vs. syringes: an online questionnaire-based study in patients with migraine

  Marcello Silvestro, Pasquale Sozio, Ilaria Orologio, Mattia Siciliano, Francesca Trojsi, Alessandro Tessitore, Gioacchino Tedeschi, Antonio Russo

  27-01-2025

  https://doi.org/10.4081/cc.2024.15772

  618

  PDF: 246

  SUPPLEMENTARY: 45

• PO-50 | Enhanced integration and synergy in EEG- and fNIRS-based networks in migraine patients following three-month galcanezumab treatment: associations with long-term clinical effects Giulia Paparella,^1,2 Marianna La Rocca,³ Livio Clemente,¹ Emmanuella Ladisa,¹ Chiara Abbatantuono,¹ Elena Ammendola,¹ Marianna Diletta Delussi,⁴ Katia Ricci,¹ Giusy Tancredi,¹ Antonio Lacalamita,³ Alfonso Monaco,³ Nicola Amoroso,⁵ Sebastiano Stramaglia,³ Roberto Bellotti,³ Marina de Tommaso¹ | ¹Neurophysiopathology Unit, Department of Translational Biomedicine and Neuroscience (DiBraiN), University of Bari Aldo Moro, Bari, Italy; ²IRCCS Neuromed, Pozzilli (IS), Italy; ³Interateneo Department of Physics "M. Merlin", University of Bari Aldo Moro, Bari, Italy; ⁴Department of Education, Psychology, Communication (For.Psi.Com.), University of Bari Aldo Moro, Bari, Italy; ⁵Department of Pharmacy–Drug Sciences, University of Bari Aldo Moro, Bari, Italy

  Società Italiana per lo Studio delle Cefalee (SISC)

  06-11-2025

  https://doi.org/10.4081/cc.2025.15872

  148

• PO-44 | Effectiveness of fremanezumab as preventive treatment of migraine up to 24 months: response rates from the Italian analysis of the PEARL study Alberto Doretti,¹ Anna Ambrosini,² Simone Braca,³ Florindo D’Onofrio,⁴ Elisa Maria Piella,⁵ Pinar Kokturk,⁶ Rosario Iannacchero⁷ | ¹Department of Neurology-Laboratory of Neuroscience, IRCCS, Istituto Auxologico Italiano, Milan, Italy; ²Mediterranean Neurological Institute NEUROMED IRCCS, Pozzilli (IS), Italy; ³Headache Centre, University of Naples “Federico II”, Naples, Italy; ⁴UOSD Stroke Unit, S.G. Moscati Hospital, Avellino, Italy; ⁵Neurosciences Department, University of Turin, Turin, Italy; ⁶Teva Netherlands B.V., Haarlem, The Netherlands; ⁷Department of Neurology, Headache Center, Regional Hospital “Pugliese-Ciaccio”, Catanzaro, Italy

  Società Italiana per lo Studio delle Cefalee (SISC)

  06-11-2025

  https://doi.org/10.4081/cc.2025.15866

  168

• OC-14 | Efficacy of eptinezumab during a migraine attack: preliminary data from an Italian multicenter real-world experience (the BEFREE study) Luisa Fofi,¹ Claudia Altamura,¹ Marilena Marcosano,¹ Alberto Doretti,² Francesca Pistoia,³ Antonio Granato,⁴ Simona Guerzoni,⁵ Michele Trimboli,⁶ Licia Grazzi,⁷ Danilo Antonio Montisano,⁷ Gianluca Avino,⁸ Gabriele Sebastianelli,⁹ Carla Fasano,¹⁰ Elisa Maria Piella,¹¹ Nicoletta Brunelli,¹ Luigi Francesco Iannone,^5,12 Fabrizio Vernieri¹ on behalf of the Italian Headache Registry (RICe) Study Group | ¹Neurosonology and Headache Unit, Fondazione Policlinico Campus Bio-Medico, Rome; ²IRCCS Istituto Auxologico Italiano - Department of Neurology and Laboratory of Neuroscience - Milan; ³University of L’Aquila; ⁴Headache Center, Neurology Clinic, University of Trieste, University Hospital of Trieste; ⁵AOU Policlinico di Modena; ⁶Azienda Ospedaliera-universitaria "Renato Dulbecco", Catanzaro; ⁷Headache Center, Neuroalgology Dpt, IRCCS Foundation "Carlo Besta" Neurological Institute, Milan; ⁸SOC Neurologia, Ospedale Santo Stefano, USL Toscana Centro, Prato; ⁹La Sapienza University of Rome Polo Pontino, Latina; ¹⁰Headache and Cerebrovascular Diseases Center, Neurology Unit 2, Careggi University Hospital, Florence; ¹¹Department of Neuroscience “Rita Levi Montalcini”, University of Turin; ¹²Università di Modena e Reggio Emilia, Italy

  Società Italiana per lo Studio delle Cefalee (SISC)

  06-11-2025

  https://doi.org/10.4081/cc.2025.15811

  341

• PO-62 | Preventive migraine treatment in patients under 25: a 24-month observational study on adherence, therapeutic switching, and prescription determinant factors Marilena Marcosano,¹ Nicoletta Brunelli,¹ Luisa Fofi,¹ Laura Papetti,² Fabiana Ursitti,² Massimiliano Valeriani,² Fabrizio Vernieri,¹ Claudia Altamura¹ | ¹Headache and Neurosonology Unit, Fondazione Policlinico Campus Biomedico di Rome, Rome, Italy; ²Developmental Neurology, Bambino Gesù Children Hospital, IRCCS, Rome, Italy

  Società Italiana per lo studio delle Cefalee (SISC)

  06-11-2025

  https://doi.org/10.4081/cc.2025.15885

  157

• PO-41 | Eptinezumab for difficult-to-treat migraine: who responds and who needs more Alessandro Visentini,^1,2,3 Roberta Messina,^1,2,3 Ilaria Cetta,^1,2,3 Edorardo Ratto,¹ Laura Zanandrea,^1,3 Federica Genovese,^1,2,3 Irene Chinali,¹ Bruno Colombo,¹ Massimo Filippi^1,2,3 | ¹Neurology Unit and ²Neuroimaging Research Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy; ³Vita-Salute San Raffaele University, Milan, Italy

  Società Italiana per lo Studio delle Cefalee (SISC)

  06-11-2025

  https://doi.org/10.4081/cc.2025.15863

  306